<\/p>\n
Asters team successfully defended interests of Teva Pharmaceutical Industries Ltd (Teva), one of the world’s largest pharmaceutical companies and generic producers, in a dispute on extension of patent term for medical product for additional 3 years over standard 20 years\u2019 term.<\/p>\n
As a result of intellectual property, litigation and pharmaceuticals law teams\u2019 work, the Supreme Court has rejected the cassation appeal of the opponents \u2013 the State Intellectual Property Service of Ukraine (Patent office) and Synthon, a major developer and producer of generics.<\/p>\n
Earlier, the team successfully defended Teva in the court of first instance and the court of appeal cancelling the refusal of the Patent office to grant patent term extension.<\/p>\n
The Patent office has extended the patent term ensuring exclusive sales of the medical product for another 3 years.<\/p>\n